WO2004092706A2 - Control bracketing and results hold for immunoanalyzer - Google Patents

Control bracketing and results hold for immunoanalyzer Download PDF

Info

Publication number
WO2004092706A2
WO2004092706A2 PCT/US2004/011327 US2004011327W WO2004092706A2 WO 2004092706 A2 WO2004092706 A2 WO 2004092706A2 US 2004011327 W US2004011327 W US 2004011327W WO 2004092706 A2 WO2004092706 A2 WO 2004092706A2
Authority
WO
WIPO (PCT)
Prior art keywords
sample
control
samples
test results
tests
Prior art date
Application number
PCT/US2004/011327
Other languages
French (fr)
Other versions
WO2004092706A3 (en
Inventor
Kouakou Diby
Lawrence A. Baker
James V. Freeman
Judith Banta
Paula Mallon
Original Assignee
Bayer Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare filed Critical Bayer Healthcare
Priority to EP20040759480 priority Critical patent/EP1616165A4/en
Priority to CA002522279A priority patent/CA2522279A1/en
Priority to JP2006509962A priority patent/JP4406426B2/en
Priority to AU2004230518A priority patent/AU2004230518A1/en
Publication of WO2004092706A2 publication Critical patent/WO2004092706A2/en
Publication of WO2004092706A3 publication Critical patent/WO2004092706A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/00584Control arrangements for automatic analysers
    • G01N35/00594Quality control, including calibration or testing of components of the analyser
    • G01N35/00603Reinspection of samples
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/00584Control arrangements for automatic analysers
    • G01N35/00594Quality control, including calibration or testing of components of the analyser
    • G01N35/00613Quality control
    • G01N35/00623Quality control of instruments
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/11Automated chemical analysis
    • Y10T436/115831Condition or time responsive

Definitions

  • This invention relates to automatic testing of biological samples, for
  • vital parameters such as the amount of fluid aspirated in a test sample
  • control samples of known material often referred to as controls, are tested in
  • test equipment such as the immunoassay analyzer.
  • control samples are the control samples
  • control tests can include the determination of the amount of acidity
  • test equipment can gradually lose accuracy during a day of testing. This
  • analyzer or assay system, provides for frequent testing of control samples to
  • This operation can be performed automatically by a random
  • control testing should be performed
  • the calibration test is performed before and after a
  • interval of time between sets of control tests may be based on experience in
  • the result of a control test can be referred to as an index representing
  • control test index can be described with reference to a
  • patient test can also be referred to as an index.
  • control testing wherein a sequence of successive runs of patient tests is
  • control tests precedes and follows a run of patient tests. For example, a first
  • the immunoassay analyzer, o ⁇ other material testing device can automatically perform the task of ensuring the accuracy of
  • Fig. 1 is a simplified flowchart showing the procedure of the
  • Fig. 2 is a timing diagram showing bracketing runs of patient tests
  • FIG. 3 is a schematic diagram of an immunoassay analyzer operating
  • FIG. 4 is a simplified flowchart similar to Fig. 1 , showing additional
  • an assay system such as a sample-testing apparatus
  • the procedure begins at block 10 with
  • the calibration test will determine
  • calibration test can involve aspirating a known quantity of liquid from a
  • control set would be run after a successful
  • control set of tests can consist of four
  • the system has a
  • control levels are not within the specified ranges.
  • block 16 is activated and the control set must be
  • block 18 is activated and the procedure advances to block 20 wherein a
  • control bracket is employed to indicate a set of
  • the "opening" of the control bracket initiates the set of patient sample tests.
  • the patient samples by means of a display, printout, or other means of
  • FIG. 2 provides a further description of the invention by means of a
  • the procedure begins with running a set of
  • slots 42 indicate individual tests. Several slots 42 are indicated by way of
  • patient samples can be tested in block 44.
  • samples of block 44 are said to bracket the testing of the patient samples of
  • control set at block 50 bracket the testing of the patient samples of block 48
  • control set at block 60 The control sets at the blocks 50 and 60 bracket
  • Fig. 2 indicates a repetition of the calibration sets of tests at less
  • FIG. 3 is a schematic diagram of a system 64 for conducting the
  • System 64 generally represents immunoassay
  • the system 64 comprises testing apparatus 66 and conveyor
  • apparatus 68 for conveying samples 70 to be tested at workstations 72 of the
  • testing apparatus 66. While the system 64 operates automatically, it is
  • the four workstations are identified as 72A, 72B, 72C and 72D.
  • Each of the workstations 72 A, 72B and 72D includes a vial 74 and an aspirator
  • workstation 72C for example, includes an aspirator 76 with a spectrometer 80
  • apparatus 66 also comprises a computer 82, a memory 106, a display 84 for
  • the conveyor apparatus 68 comprises two input conveyor belts 88
  • the selector 92 and 90 coupled by a selector 92 to a third conveyor belt 94.
  • the selector 92
  • the conveyor belts 88, 90 and 94 are supported by a plurality
  • a drive unit 102 operated by signals from the computer 82, is shown
  • the sample holders 104 located on the first input conveyor belt 88,
  • sample holders 104 located on the second input conveyor belt 90, carry
  • control samples to be tested by the system 64 Some of the control samples on
  • the second input conveyor belt 90 can be employed for conducting the
  • the selector 92 operated by the computer 82 provides for an
  • the computer 82 directs the selector
  • the computer 82 directs the
  • selector 92 to select the samples 70 of the first belt 88 to be coupled onto the third belt 94 for conducting the patient sample tests as described above with
  • the holders 104 contain
  • workstations 72 can be tested during a calibration test by measuring the liquid
  • the sensor 78 can also be any material, within the respective vial 74.
  • the sensor 78 can also be any material, within the respective vial 74.
  • the sensor 78 can also be any material, within the respective vial 74.
  • the sensor 78 can also be any material, within the respective vial 74.
  • the sensor 78 can also be any material, within the respective vial 74.
  • the sensor 78 can also be any material, within the respective vial 74.
  • the computer 82 directs the conveyor drive unit 102 to bring the
  • the aspirators 76 aspirate predetermined quantities of the samples 70 into the
  • the computer 82 controls the computer 82.
  • the computer also directs the store 86 to inject
  • the of the vials 74 can produce, for example, a change in color, a change in
  • the aspirator 76 is supplied to the spectrometer 80, and spectrographic data
  • control set of block 50 there can be an announcement of the test results of the
  • a program for operation of the computer 82 may
  • Fig. 4 shows procedural operations which are in addition to and
  • the patient tests are not to be released and are to be withheld, or quarantined, until a later time when the results of the calibration tests, the control tests
  • control tests are running. If the control test set is not being run, then at block
  • control set is run, which is the control set that follows the patient tests
  • control test are about 24 hours.
  • control set reach a predetermined age, such as 24 hours, all patient tests in
  • a time of 24 hours is generally set for
  • the user can set the time interval as desired.
  • the calibration tests are then rerun at block 120.
  • block 154 to inquire whether there are any patient tests currently in progress.

Landscapes

  • Engineering & Computer Science (AREA)
  • Quality & Reliability (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

An automated immunoassay analyzer, or assay system, provides for frequent testing of control samples to verify that before and after a series of tests of patients' samples, the operation of the test equipment is accurate, thereby ensuring that the results of the series of patient tests are accurate. Operating the immunoassay analyzer in this manner will delay reporting clinical test results until the results are confirmed as accurate. This operation can be performed automatically by a random access immunoassay analyzer.

Description

CONTROL BRACKETING AND RESULTS HOLD
BACKGROUND OF THE INVENTION
[0001] This application claims the benefit of U.S. Provisional Application
No. 60/463,101 filed April 15, 2003.
[0002] This invention relates to automatic testing of biological samples, for
example, the use of an immunoassay analyzer for medical tests on human
subjects and, more particularly, to coordinating the testing of control samples
with the testing of patient samples to insure accuracy of the patient sample test
results.
[0003] Testing of biological material is widely employed in the practice of
medicine, as well as in other disciplines wherein information about biological
material is required. Of particular interest is automated testing for the presence
of disease in samples of biological material from human patients. Such testing
is frequently accomplished by the use of automated equipment, such as an
immunoassay analyzer, wherein samples of bodily fluids obtained from
patients are aspirated into the testing machinery which then performs tests and
provides the results of those tests.
[0004] The testing and reporting of the results must be performed accurately
to insure that patients receive proper treatment, and to avoid faulty diagnosis
of the patient's condition. In order to insure accuracy in the testing procedure, equipment employed in the testing process must be calibrated to ensure that
vital parameters, such as the amount of fluid aspirated in a test sample, the
temperature of an aspirated sample, and other parameters deteririined by the
testing equipment are measured correctly.
[0005] In order to ensure the necessary accuracy in the testing procedure,
control samples of known material, often referred to as controls, are tested in
the test equipment, such as the immunoassay analyzer. The control samples
typically contain biological material of known composition, to ensure that the
testing equipment is operating properly and providing the correct results. For
example, control tests can include the determination of the amount of acidity
in the control material, or the presence of spectral lines in a spectroscopy
examination of the control material.
[0006] Generally, the calibration and control runs are made before starting
the patient's tests, such as at the beginning of the day. Then, the results of
patient tests conducted during the day can be presumed to be valid. However,
test equipment can gradually lose accuracy during a day of testing. This
presents a problem because the results of tests conducted later in the day may
be invalid or inaccurate. Thus, there is a need for a procedure to provide
improved monitoring of the operation of the testing equipment on a relatively
continuous basis to ensure that the testing equipment is operating accurately
even after a relatively short series or run of patient tests. SUMMARY OF THE INVENTION
[0007] In accordance with the present invention an automated immunoassay
analyzer, or assay system, provides for frequent testing of control samples to
verify that before and after a series of tests of patients' samples, the operation
of the test equipment is accurate, thereby ensuring that the results of the series
of patient tests are accurate. Operating the immunoassay analyzer in this
manner will delay reporting clinical test results until the results are confirmed
as accurate. This operation can be performed automatically by a random
access immunoassay analyzer.
[0008] In practicing the invention, the control testing should be performed
more frequently than the calibration testing because the immunoassay analyzer
tends to retain its calibration ability for longer periods of time than its
capability to maintain the accuracy of its performance of the control tests.
[0009] Accordingly, the calibration test is performed before and after a
relatively long series of patient tests, whereas the control testing is performed
before and after a relatively short series of patient tests. For example, it can be
desirable to run a series or set of control tests once every hour, wherein the
interval of time between sets of control tests may be based on experience in
operating the immunoassay analyzer. [0010] The result of a control test can be referred to as an index representing
a numerical value. The control test index can be described with reference to a
window or range of acceptable indices such that, depending on the specific
test, a control test index is required to fall within the window. The result of a
patient test can also be referred to as an index.
[0011] In a preferred embodiment of the invention, three different control
tests are performed where the indices are to fall within the window, and a
single control test can be provided for an index falling below the lower
boundary of the window, and a further single control test can be provided for
an index falling above the upper boundary of the window.
[0012] The procedure of the invention can be demonstrated with respect to
the control testing, wherein a sequence of successive runs of patient tests is
bracketed or interleaved with a sequence of sets of control tests. Thus, a set of
control tests precedes and follows a run of patient tests. For example, a first
set of control tests and a second set of control tests bracket a first run of patient
tests.
[0013] After the second set of control tests, the patient tests are resumed until
a third set of control tests is run. Thus, the second and the third set of control
tests bracket the second run of patient tests. The two sets of control 'tests that
bracket a specific run of. patient tests . must show proper operation of the immunoassay analyzer in order to validate the results of the run of patient
tests, and enable the reporting of the results of the patient tests.
[0014] In the event that the analyzer has not performed the set of control
tests that follow a run of patient tests over an extended period of time, for
example, 10 hours, then the results of the patient tests of that run are discarded
because the late testing of controls may not represent the current status of the
analyzer for patient tests conducted several hours earlier.
[0015] It is recognized that an interval of incubation time that can vary from
about 15 to about 45 minutes is required after the aspiration of a set of control
tests in order to establish the results of the control tests. To save time, it can be
desirable to resume the patient testing, rather than wait until the results of the
control tests have been established. Thus, patient sample aspirations do not
have to await control test, results before starting, only that the control has
already been aspirated.
[0016] If the control tests show a defective, analyzer, then the results of the
patient testing in the run of patient tests which preceded the defective control
results, as well as the results of the patient testing in the run of patient tests
which followed the defective control results are discarded.
[0017] By interleaving or bracketing the sequence of runs of patient tests
■ with the sequence of control tests, the immunoassay analyzer, oχ other material testing device can automatically perform the task of ensuring the accuracy of
the patient test results before reporting the results.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In the drawings:
[0019] Fig. 1 is a simplified flowchart showing the procedure of the
invention for interleaving a sequence of tests during the performance of an
immunoassay analyzer with a sequence of runs of patient tests for confiπning
the accuracy of the results of the patient tests prior to reporting the results;
[0020] Fig. 2 is a timing diagram showing bracketing runs of patient tests
with sets of control tests to implement the procedure of Fig. 1 ;
[0021] Fig. 3 is a schematic diagram of an immunoassay analyzer operating
in accordance with the procedure of the invention; and
[0022] Fig. 4 is a simplified flowchart similar to Fig. 1 , showing additional
options and features of the invention.
[0023] Identically labeled elements appearing in different figures refer to the
same element but may not be referred to in the description for all figures. DETAILED DESCRIPTION OF THE INVENTION
[0024] With reference to Fig. 1, the procedure of the invention is applicable
to the operation of an assay system, such as a sample-testing apparatus, and
more particularly to the automated immunoassay analyzer employed in a
preferred embodiment of the invention. The procedure begins at block 10 with
a calibration of the assay system. Typically, the calibration test will determine
whether the volume of a quantity of liquid or the acidity of the liquid (pH
value), for example, is being correctly measured by the assay system
equipment. In the case of the automated immunoassay analyzer, the
calibration test can involve aspirating a known quantity of liquid from a
sample followed by comparing the measured value of the quantity of liquid
with the known quantity.
[0025] The results of the calibration step can be awaited before proceeding
with block 12 or, if desired, one can proceed immediately to block 12 and run
a control set of system tests. If the results of the calibration tests are awaited
before running the control set, the control set would be run after a successful
completion of the calibration tests. Calibration tests are used to establish
measurement parameters, whereas control tests are used to make sure that the
analyzer is operating properly with the established parameters. [0026] If the calibration tests indicate a problem with the assay system,
appropriate adjustments would be made to obtain proper calibration prior to
running the control set. However, if the assay system had been recently tested,
and it is presumed that the assay system is operating properly, some patient
tests can be conducted with the results withheld until the results of the
calibration and of the control set have been ascertained. Thereafter, the results
can be provided to the patient or to the health-care provider, such as by use of
a display or printer of the assay system. If there is a failure of a calibration test
or a failure of a test of the control set, the patient tests would need to be rerun,
and the results of the prior patient tests would be discarded.
[0027] For example, at block 12, the control set of tests can consist of four
samples of known material to be applied to four separate tests with four
separate reagents and possibly a spectrographic test. In the use of the control
set, the correct results are known beforehand. Thus, if the assay system
produces the correct results from the tests, the outputting of the correct results
is an indication of proper and accurate operation of the assay system.
[0028] Each test of the control set is formulated to provide a numerical result
that must fall within a range of values. For example, a numerical result must
fall within a window of acceptable results, the window extending from a lower
limit to an upper limit of acceptable values. Alternatively, an acceptable value
must fall in a range below an upper limit or in a range above a lower limit. [0029] Thus, in the case of an automated assay system, the system has a
computer to compare the results of a control test with the acceptable range of
values and outputs an indication of a successful test or a failed test. Similarly,
in the case of a calibration test run in block 10, the computer tests a measured
value, such as the volume of a liquid or the acidity of the liquid against the
known validity criteria to output the indication of a successful test or a failed
test.
[0030] If both the calibration tests and the control tests are run prior to the
inception of the patient testing, the procedure of Fig. 1 advances to block 14
wherein it is determined whether the measured levels in the tests of the control
set are within the specified ranges. In the event that the control levels are not
within the specified ranges, block 16 is activated and the control set must be
rerun at block 12. In the event that the control levels are within the specified
ranges, block 18 is activated and the procedure advances to block 20 wherein a
control bracket is opened.
[0031] The terminology "control bracket" is employed to indicate a set of
patient sample tests preceded by a control set and followed by a control set.
The "opening" of the control bracket initiates the set of patient sample tests.
The "closing" of the control bracket terminates of the set of patient sample
tests. . [0032] At block 22, the set of tests on the patient samples is run. In
accordance with one aspect of the invention, the reporting of the test results of
the patient samples by means of a display, printout, or other means of
communication is withheld until the control bracket is successfully closed.
[0033] The "successful closing" of the control bracket means that the
concluding set of control tests, which follows the set of the patient tests,
indicates that the assay system is operating correctly.
[0034] Accordingly, at block 24, the control set that follows the set of the
patient tests is activated. At block 26 it is determined whether all the control
levels of the control set at block 24 are in the specified ranges. If the control
levels are within the specified ranges at block 28, then the control bracket is
successfully closed at block 30, and the patient results are released, such as by
presentation on a display or printout of the assay system.
[0035] In the event that the control levels are not within the specified ranges
at block 32, then, at block 34, there is a purging of the patient results from the
assay system, and the procedure reverts to block 12 for a running of the control
set-
[0036] • It should also be noted that at the time of the initial calibration of the
assay system at block 10, if there are previous patient results that have been
withheld, then these patient results should be purged from the assay system at
block 34 prior to commencing the running of the control set at block 12. This ensures that there is no inadvertent release of patient data where it has not been
ascertained that the data is accurate.
[0037] Fig. 2 provides a further description of the invention by means of a
timing diagram showing the succession of steps in the procedure. As shown at
the top of the diagram, at block 36, the procedure begins with running a set of
calibration tests, with individual tests indicated by slots 38.
[0038] Upon completion of the calibration tests, the procedure advances to
block 40 for performance of the sequence of tests of the control set. Individual
tests of the control set are indicated by slots 42.
[0039] Upon completion of the control set, the procedure advances to block
44 for performance of the sequence of tests on patient samples. In block 44,
slots 42 indicate individual tests. Several slots 42 are indicated by way of
illustration to represent that in actual. practice of the invention, hundreds of
patient samples can be tested in block 44.
[0040] Upon completion of the sequence of patient tests of block 44, the
procedure continues at block 46, wherein individual tests of the control set are
indicated by slots 42. This is followed by a further sequence of testing of
patient samples at block 48 which, in turn, is followed by the running of tests
of a further control set at block 50. [0041] The sequence of tests of the control set of block 40, which precedes
the sequence of the testing of the patient samples at block 44, and the sequence
of tests of the control set of block 46, which follows the testing of the patient
samples of block 44, are said to bracket the testing of the patient samples of
block 44, such bracketing being indicated at 52.
[0042] Correspondingly, the control set at block 46 and the subsequent
control set at block 50 bracket the testing of the patient samples of block 48,
this bracketing being indicated at 54.
[0043] The timing diagram of Fig. 2 shows a further testing of patient
samples at block 56 followed by calibration tests at block 58 followed by a
further control set at block 60. The control sets at the blocks 50 and 60 bracket
the patient samples at block 56 as indicated at 62. Upon the successful
conclusion of the bracket 52, there is an announcement of the results of the
testing of the patient samples at block 44 of the bracket 52. Similarly, there is
an announcement of the results of the patient samples of block 48 upon the
successful conclusion of its bracket 54, and an announcement of the results of
the testing of the patient samples of the block 56 upon a successful conclusion
of its bracket 62.
[0044] In the event that calibration tests, such as the calibration tests at block
58 of the bracket 62, indicate a need for recalibration, the results of the tests of the patient samples of block 56 are discarded, as indicated at arrow 59, and are
not announced. Only samples between control sets using the same accurate
calibration parameters are released. The handling of the recalibration situation
will be described further with reference to Fig. 4.
[0045] Fig. 2 indicates a repetition of the calibration sets of tests at less
frequent intervals than the rate of repetition of the control sets of tests. Thus,
there is an interleaving of sequences, of tests of the calibration sets and of the
control sets and of the patient sample sets.
[0046] Fig. 3 is a schematic diagram of a system 64 for conducting the
procedure of the invention. System 64 generally represents immunoassay
equipment including the immunoassay analyzer of the invention. It is
understood that the specific components of such equipment may vary
depending on the needs of the user of the equipment.
[0047] The system 64 comprises testing apparatus 66 and conveyor
apparatus 68 for conveying samples 70 to be tested at workstations 72 of the
testing apparatus. 66. While the system 64 operates automatically, it is
understood that the procedure of the invention can also apply to manually
operated equipment.
[0048] By way of example in the system 64, four workstations 72 are shown.
It is understoo.d that a greater or lesser number of workstations can be employed. The four workstations are identified as 72A, 72B, 72C and 72D.
Each of the workstations 72 A, 72B and 72D includes a vial 74 and an aspirator
76 for extracting into the vial 74 a predetermined portion of a sample to be
tested, as well as a sensor 78 for sensing the contents of the vial 74. The
workstation 72C, for example, includes an aspirator 76 with a spectrometer 80
for determining the spectral characteristics of an aspirated sample. The testing
apparatus 66 also comprises a computer 82, a memory 106, a display 84 for
outputting results of a test, and a store 86 for storing reagents to the placed in
the vials 74 for conducting the tests.
[0049] The conveyor apparatus 68 comprises two input conveyor belts 88
and 90 coupled by a selector 92 to a third conveyor belt 94. The selector 92
can be a mechanical switch which offsets the position of either one of the input
belts 88 and 90 to be in alignment with the third belt 94, to thereby enable
articles carried by one of the selected input belts 88 and 90 to be passed on to
the third belt 94. The conveyor belts 88, 90 and 94 are supported by a plurality
of drive rolls, two of which are shown at 96 and 98, for imparting motion to
the belts in the direction of arrow 100.
[0050] A drive unit 102, operated by signals from the computer 82, is shown
connected to the roll 98 for imparting rotation to the roll 98 to carry sample
holders 104 along the third conveyor belt 94. It is understood that further connections, not shown, are provided between the drive unit 102 and other
drive rolls of the conveyor apparatus 68 for selectively driving the input belts
88 and 90.
[0051] The sample holders 104, located on the first input conveyor belt 88,
carry patient samples to be tested by the conveyor apparatus 68 while further
sample holders 104, located on the second input conveyor belt 90, carry
control samples to be tested by the system 64. Some of the control samples on
the second input conveyor belt 90 can be employed for conducting the
calibration tests of the system 64.
[0052] The selector 92 operated by the computer 82 provides for an
alternative coupling of sample holders 104 of either the first conveyor belt 88
or the second conveyor belt 90 to the third conveyor belt 94.
[0053] In the operation of the system 64, the computer 82 directs the selector
92 to select the samples 70 of the second belt 90 to be coupled onto the third
belt 94 for conducting the calibration tests as described above with reference to
block 36 of Fig. 2, and also for conducting the tests of a control set as
described above with reference to block 40 of Fig. 2.
[0054] For conducting tests on patient samples, the computer 82 directs the
selector 92 to select the samples 70 of the first belt 88 to be coupled onto the third belt 94 for conducting the patient sample tests as described above with
reference to block 44 of Fig. 2.
[0055] With respect to conducting any one of the tests, whether a calibration
test or a test of the control set, or a patient sample test, the holders 104 contain
a known quantity of the samples 70. A sensor 78 in any one of the
workstations 72 can be tested during a calibration test by measuring the liquid,
or other material, within the respective vial 74. The sensor 78 can also be
employed in a control test or a patient sample test to measure the amount of
product or other characteristic of a chemical reaction within the respective vial
74. By operation of the selector 92, in combination with activation of the
conveyor drive unit 102, the computer is able to sequence the procedures
conducted by the system 64 in accordance with the format presented in the
timing diagram of Fig. 2.
[0056] The computer 82 directs the conveyor drive unit 102 to bring the
sample holders 104 to respective locations under the aspirators 76, whereupon
the aspirators 76 aspirate predetermined quantities of the samples 70 into the
vials 74. Alternatively, a single sample 70 can be processed by successive
workstations 72A, 72B, 72C and 72D wherein each workstation performs a
separate test on the specific sample. The operation of an aspirator 76 is
controlled by the computer 82. The computer also directs the store 86 to inject
predetermined amounts of reagents into respective ones of the vials 74. [0057] The chemical reaction between the reagent and the sample in any one
of the vials 74 can produce, for example, a change in color, a change in
temperature, or a quantity of precipitate which can be sensed by the sensor 78.
[0058] In the case of the workstation 72C, material of a sample aspirated by
the aspirator 76 is supplied to the spectrometer 80, and spectrographic data
outputted by the spectrometer 80 is transmitted to the computer 82. Values
sensed by the sensor 78 are transmitted to the computer 82 for evaluating the
results of the tests.
[0059] In accordance with another aspect of the invention, the results of the
tests on the patient samples are held within the memory 106 of the computer
82 until the closing of a bracket, as described in Fig. 2, prior to being
transmitted to the display 84.
[0060] The results are presented on the display 84, or otherwise
communicated such as by being printed by a printer of the display 84 or being
transmitted electronically to a remote station, only after a successful closure of
the bracket.
[0061] As already described, successful closure of the bracket only occurs
when the tests of the control sets conducted both before and after a sequence of
patient samples tests are found to produce acceptable results. [0062] This is demonstrated in Fig. 2 wherein, after a successful conclusion
of the control set of block 46, there maybe an announcement of the test results
of the patient samples of block 44. Also, after successful conclusion of the
control set of block 50 there can be an announcement of the test results of the
patient samples of block 48. A program for operation of the computer 82 may
also be stored in the memory 106, providing for operation of the system 64
under direction of the computer 82 in accordance with the invention.
[0063] Fig. 4 shows procedural operations which are in addition to and
alternative to the procedural operations disclosed in Fig. 1. The procedure
begins at block 120 with a running of the calibration tests of the immunoassay
analyzer. This is followed at block 122 with the running of the control set for
the immunoassay analyzer. Thereupon, at block 124, there is a running of the
sequence of the patient sample tests, wherein the results of the patient tests are
quarantined by holding the results in the computer memory 106 of Fig. 3. In
the example of the operation of the assay equipment presented by the sequence
of blocks 120, 122 and 124, the patient tests have been run immediately after
the running of the calibration tests and the control tests.
[0064] In this example, the patient tests have been run before obtaining the
results of the calibration tests and the control tests. Therefore, the results of
the patient tests are not to be released and are to be withheld, or quarantined, until a later time when the results of the calibration tests, the control tests
preceding the patient tests, and a further set of control tests which follow the
patient tests have been obtained and are found to be accurate.
[0065] Thus, at block 126 it is determined whether any calibration tests are
still being run. In the event that calibration tests are still being run, at block
128 the procedure waits until the results of the calibration tests are obtained
and evaluated.
[0066] In the event that the calibration is found to be valid at block 130, the
procedure advances to block 132 where it is determined whether the set of
control tests are running. If the control test set is not being run, then at block
134 the control set is run, which is the control set that follows the patient tests
of block 124. The procedure then waits for the results of the control tests to be
evaluated at block 136. If the results of the control set are in their proper
ranges at block 138, the procedure advances to block 140 to observe whether
there are any patient test results in quarantine, namely, being stored in the
computer memory 106 of Fig. 3.
[0067] In the situation under consideration, patient tests were run at block
124, and the results were quarantined. Accordingly, the procedure advances
from block 140 to block 142 wherein the patient test results are released from
quarantine. [0068] The releasing from quarantine is accomplished in Fig. 3 by a reading
of the results from memory 106 for presentation on the display 84.
[0069] After announcing the patient test results at block 142, the procedure
can then revert via blocks 144, 146 and 148, to run more patient tests at block
124. At block 144 it is determined whether it is necessary to recalibrate the
assay equipment. In the situation under consideration, the equipment has been
recently recalibrated at block 120. Therefore, it is not necessary to recalibrate
at this time, and the procedure advances to block 146 wherein it is determined
whether any of the control test results which bracket the patient test results are
too old. This is determined by a time comparison. Typical specific time
parameters that serve as criteria to recalibrate are about 14 days and to rerun a
control test are about 24 hours.
[0070] In the situation under consideration, all the control tests were run
recently, and the procedure advances to block 148 to determine whether there
are additional patient tests to be run. If more patient tests are to be run, then
the procedure advances to block 124 for rurr-iing more patient tests.
[0071] It is noted that at any point in the process, when the results of a
control set reach a predetermined age, such as 24 hours, all patient tests in
progress, as well as patient results which were quarantined after the control
results were evaluated, are discarded instantly if still quarantined. This ensures that only recent control test results are employed for ensuring the testing
accuracy of the patient samples. A time of 24 hours is generally set for
default. However, the user can set the time interval as desired.
[0072] Variations in the foregoing procedure are now considered.
Previously, at block 126, it was said that the assay calibration tests were still
rur-ning. However, in the event that the calibration tests are not currently
running, the procedure advances from block 126 to block 130 to determine
whether the previously completed calibration runs produced valid results.
[0073] At block 130, it was previously assumed that the calibration was
valid. However, in the event that the calibration tests results are not in their
appropriate ranges, the procedure reverts via block 150 to block 120. At block
150 the patient test results which were quarantined are discarded, this being
accomplished in Fig. 3 by a dumping or erasing of the patient test results from
the memory 106. The calibration tests are then rerun at block 120.
[0074] In reference to a further possible situation, one may begin the
procedure at block 120 shortly after having run some patient tests, which were
properly bracketed by control tests, after which further patient samples were
presented for testing. In this situation, it is not necessary to rerun the
calibration tests, but simply to check the results of the calibration tests at block
128. This step of the procedure is indicated by a line connecting block 120
with block 128. [0075] In the previous discussion of block 132, it was assumed that the
tests of the control set were not running and, accordingly, the tests were run at
block 134. In this connection, it is noted that additional sets of the control tests
can be run from time to time to insure accuracy of the results of the patient
tests. If, at block 132, it were noted that tests of the control set are presently
running, then the procedure would advance from block 132 directly to block
136 to await evaluation of the results of the control set.
[0076] In the previous discussion of block 138, it was assumed that the
results of the control tests were in the proper range, in which case the
procedure advanced from block 138 to block 140. However, in the situation
wherein there are results of the control tests that are not in the proper ranges,
the procedure* advances to block 152 wherein the results of the patient tests,
which are held in quarantine, are discarded, and the procedure reverts to block
130 to determine if the results of the calibration tests are valid.
[0077] In the previous discussion of block 140, it was assumed that there
were patient results to be released from quarantine. However, in the situation
wherein there are no patient results in quarantine, the procedure advances to
block 154 to inquire whether there are any patient tests currently in progress.
If patient tests are currently in progress, then the procedure reverts from block
154 to block 130 to determine if the results of the calibration tests are valid. If,
at block 154, it is determined that no patient tests are presently in progress, then the procedure advances to block 146 wherein, as described above, it is
determined whether the most recent valid control results are too old. The
specific time parameters for "too old" are determined by the user. As noted
above in a previous example of aging test results, when the results of a control
set reach a determined age, such as 24 hours, all patient tests in progress, as
well as patient results which were quarantined after the control results were
evaluated, were also discarded if still quarantined.
[0078] At block 144, in the previous description, it was assumed that there
was no need to recalibrate the assay equipment, in which case the procedure
advanced to block 146. However, at block 144, if it is determined to be
necessary to recalibrate the assay equipment, then the procedure advances via
block 156 back to block 120. At block 156, there is a discarding of results of
any patient tests which may be in progress or which may be in quarantine,
after which the calibration tests of the assay equipment are rerun at block 120.
[0079] At block 146, in the previous description, it was assumed that the
most recent valid results of control tests were timely. Therefore, the procedure
could advance to block 148 to deterrnine if there were more patient tests to be
run. However, in the event that results of the most recent control tests are too
old, then the procedure reverts from block 146 to block 122 for a rerunning of
the tests in the control set. At block 148, if there are no more patient tests to be run, then the procedure recycles back through block 146 in a waiting loop
until more patient samples arrive for testing.
[0080] It is to be understood that the above described embodiments of the
invention are illustrative only, and that modifications thereof may occur to
those skilled in the art. Accordingly, this invention is not to be regarded as
limited to the embodiments disclosed herein, but is to be limited only as
defined by the appended claims.

Claims

What is claimed is:
1. A sample testing system comprising:
(a) testing means for analyzing properties and characteristics of
samples, said testing means including a workstation with means for
extracting and analyzing predetermined portions of samples including:
(i) a first control sample having known properties and
characteristics;
(ii) a sample of organism biological material having
unknown properties and characteristics;
(iii) a second control sample having known properties and
characteristics;
(b) conveyor means cooperable with the testing means,
including means for sequencing said samples to the workstation for
analyzing samples to obtain test results for each sample in the following
order: first control sample, sample of organism biological material, second
control sample;
(c) computer means cooperable with the conveyor means and
the testing means, including memory means;
(d) program means to enable the computer, means to:
(i) compare the test results of the first control sample with
its known properties and characteristics of the first control sample to confirm the accuracy of the testing
means;
(ii) collect and store the test results for the sample of
organism biological material in the memory means,
after confirming the accuracy of the first control
sample; '
(iii) compare the test results of the second control sample
with its known properties and characteristics to again
confirm the accuracy of the testing means, after
collecting and storing the test results for the sample of
organism biological material in the memory means.
2. The system of claim 1, including information presentation
means cooperable with the computer means to provide a visual presentation
of the test results of the sample of organism biological material after the
program means confirms the accuracy of the test results for the first and
second control samples.
3. The system of claim 1, further comprising extracting means
for extracting a predetermined amount of each sample for analysis.
4. The system of claim 3, further comprising measuring means
cooperable with the extracting means for measuring a predetermined
quantity of an extracted sample, and adjusting means to calibrate the
measuring means of the test apparatus.
5. The system of claim 2, wherein the program means
withholds test results on the samples of organic biological material until
completion of all tests on the control samples that bracket the tests of the
samples of organic biological material.
6. The system of claim 5, wherein, upon a failure of a test on
any one of the control samples of the bracket, the program means discards
the test results of the samples of organic biological material.
7. A method for testing a sample of biological organism
material comprising:
(a) testing a first control sample having known properties and
characteristics with testing means to analyze the known properties and
characteristics of said first control sample to obtain first test results;
(b) comparing the first test results with the known properties
and characteristics of the first control sample to confirm the accuracy of the
testing means; (c) after confirming the accuracy of the testing means on the
first control sample, testing a sample of biological organism material with
the testing means to analyze its properties and characteristics of the
biological organism material and to obtain second test results, and storing
the second test results while refraining from a disclosure of the second test
results;
(d) after storing the second test results, testing a second control
sample having known properties and characteristics with the testing means
to analyze the properties and characteristics of the second control sample to
obtain third test results;
(e) comparing the third test results with the known properties
and characteristics' of the second control sample to again confirm the
accuracy of the testing means;
(f) after confirming the accuracy of the testing means on the
second control sample, disclosing the second test results of the sample of
biological organism material.
8. The method of claim 7, wherein the sample of biological
organism material and the first and second control samples are sequenced to
the testing means in a manner wherein the test results obtained for the first
and second control samples interleave the test results for the sample of
biological organism material.
9. The method of claim 7, further comprising calibrating the
testing means.
10. The method of claim 7, further comprising extracting a
predetermined amount of each sample by aspiration for analysis by the
testing means.
11. The method of claim 7, wherein the test results for each
control sample are characterized by an index representing a numerical value.
12. The method of claim 11, wherein a range of acceptable
indices falls within a window represented by upper and lower pre-
established numerical limits.
13. The method of claim 7, wherein an unacceptable index is
represented by a numerical value that is outside the range of acceptable
indices.
14. The method of claim 13, wherein when an unacceptable
index occurs for the control sample that is tested immediately following the
test results of the sample of organism biological material, the test results for
the organism sample are discarded.
15. The method of claim 14, wherein after the test results of the
sample of organism biological material are discarded, new testing of first
and second control samples is initiated to bracket a new test of the organism
sample of biological material.
16. The method of claim 7, wherein a first set of control
samples precedes a run of samples of organic biological material and a
second set of control samples follows a run of the test samples of organic
biological material to bracket the test results of the samples of organic
biological material, wherein each sequence of test results for the samples of
organic biological material are bracketed by tests of the control samples to
insure accuracy of the test results of the samples of organic biological
material.
17. The method of claim 12, wherein the test results on the
samples of organic biological material are withheld from disclosure until
completion of all tests on the control samples that bracket the tests of the
samples of organic biological material.
18. The method of claim 17, wherein, upon the failure of a test
on any one of the control samples of the bracket, the test results of the
samples of organic biological material are discarded.
PCT/US2004/011327 2003-04-15 2004-04-13 Control bracketing and results hold for immunoanalyzer WO2004092706A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP20040759480 EP1616165A4 (en) 2003-04-15 2004-04-13 Control bracketing and results hold
CA002522279A CA2522279A1 (en) 2003-04-15 2004-04-13 Control bracketing and results hold
JP2006509962A JP4406426B2 (en) 2003-04-15 2004-04-13 Batch control and result retention
AU2004230518A AU2004230518A1 (en) 2003-04-15 2004-04-13 Control bracketing and results hold

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46310103P 2003-04-15 2003-04-15
US60/463,101 2003-04-15
US10/817,998 2004-04-05
US10/817,998 US20040209375A1 (en) 2003-04-15 2004-04-05 Control bracketing and results hold

Publications (2)

Publication Number Publication Date
WO2004092706A2 true WO2004092706A2 (en) 2004-10-28
WO2004092706A3 WO2004092706A3 (en) 2006-02-02

Family

ID=33162291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011327 WO2004092706A2 (en) 2003-04-15 2004-04-13 Control bracketing and results hold for immunoanalyzer

Country Status (6)

Country Link
US (2) US20040209375A1 (en)
EP (1) EP1616165A4 (en)
JP (2) JP4406426B2 (en)
AU (1) AU2004230518A1 (en)
CA (1) CA2522279A1 (en)
WO (1) WO2004092706A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148607A1 (en) * 2006-06-19 2007-12-27 Olympus Corporation Analyzing apparatus, analyzing method and analyzing program

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505873B (en) * 2005-08-24 2011-12-28 泰利化学公司 A method of testing a liquid sample, a test unit, and an automized system of a plurality of test units
US8868353B2 (en) * 2007-02-02 2014-10-21 Beckman Coulter, Inc. System and method for testing autoverification rules
US8112232B2 (en) * 2007-02-02 2012-02-07 Beckman Coulter, Inc. System and method for autoverifying laboratory test results
US8652051B2 (en) * 2007-04-04 2014-02-18 Brunswick Corporation Contact pressure sensing apparatus for use with exercise equipment sensors
JP5405378B2 (en) * 2010-04-09 2014-02-05 株式会社日立ハイテクノロジーズ Nucleic acid analyzer and method
JP6374148B2 (en) * 2013-08-30 2018-08-15 シスメックス株式会社 Sample analyzer and sample analysis method
CN111356927B (en) * 2018-03-16 2024-04-19 株式会社日立高新技术 Automatic analysis device and analysis method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954012A (en) * 1973-03-05 1976-05-04 Varian Associates Automatic sampler apparatus
US4109505A (en) * 1974-07-22 1978-08-29 Primary Children's Hospital Automated blood analysis system
EP0871034B1 (en) * 1997-04-10 2007-03-07 Hitachi, Ltd. Automatic analyzer and support system therefor
JP3456162B2 (en) * 1999-03-24 2003-10-14 株式会社日立製作所 Automatic analyzer
JP3598019B2 (en) * 1999-06-16 2004-12-08 株式会社日立製作所 Automatic analyzer
US6748337B2 (en) * 2001-03-14 2004-06-08 Wardlaw Partners, Lp Method and apparatus for providing quality control in an instrument for medical analysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1616165A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007148607A1 (en) * 2006-06-19 2007-12-27 Olympus Corporation Analyzing apparatus, analyzing method and analyzing program
JP2007333700A (en) * 2006-06-19 2007-12-27 Olympus Corp Analyzing device, analyzing method, and analyzing program
US8321142B2 (en) 2006-06-19 2012-11-27 Beckman Coulter, Inc. Analyzer, analysis method and computer program product

Also Published As

Publication number Publication date
EP1616165A2 (en) 2006-01-18
CA2522279A1 (en) 2004-10-28
US20110294221A1 (en) 2011-12-01
JP2006523842A (en) 2006-10-19
US20040209375A1 (en) 2004-10-21
JP2010032530A (en) 2010-02-12
EP1616165A4 (en) 2011-10-12
AU2004230518A1 (en) 2004-10-28
WO2004092706A3 (en) 2006-02-02
JP4406426B2 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
US20110294221A1 (en) Control bracketing and results hold
US20080312859A1 (en) Method of Calibrating a System for Measuring the Concentration of Substances in Body and an Apparatus for Exercising the Method
EP1036335B1 (en) Method of verifying aspirated volume in automatic diagnostic system
EP3144678B1 (en) Automated analysis device
JP2524454B2 (en) Analyzer for automatic analysis of body fluids
EP1059535A1 (en) Method of indicating an error condition of a volume-controlled automatic aspirator
CN115112910A (en) Automatic analysis device and automatic analysis method
EP2932234B1 (en) Calibration process and system
HK1057687A1 (en) Strip containing a series of fluid sampling and testing devices and method of making packaging and using it
US20060275906A1 (en) Method for ascertaining interferents in small liquid samples in an automated clinical analyzer
EP4036573A1 (en) Method of detecting the presence or absence of a clot in a liquid sample analyzer
EP4265185A1 (en) Method of detecting presence or absence of a clot in a liquid sample analyzer
JP2000275249A (en) Automatic analyzer
US6463394B1 (en) Method for calibration and measurement in a micro-dialysis system, and a micro-dialysis system
JP7462048B2 (en) Diagnostic analyzers and quality control methods
WO2004040284A1 (en) Method of performing calibration and quality control of a sensor and apparatus for performing said method
KR20150057181A (en) Method of in vitro automatic diagnostics
EP4265184A1 (en) Temperature calibration
US20240264193A1 (en) Dispensing Device, Automatic Analysis Device, and Dispensing Method
CN114646765A (en) Test tube detection control method, device, equipment and medium
CN111295590A (en) Analysis method, calibration curve creation method, and coagulation analysis device
JPH0654319B2 (en) Automatic analyzer
EP1553868A1 (en) Apparatus for monitoring a patient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004759480

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004230518

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2522279

Country of ref document: CA

Ref document number: 2006509962

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004230518

Country of ref document: AU

Date of ref document: 20040413

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004230518

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004759480

Country of ref document: EP